Notifications
Back

XAFTY®

A broad-spectrum antiviral for XAFTY®


XAFTY®

A broad-spectrum antiviral for XAFTY®

The Need For XAFTY®

New technologies open new possibilities 

Throughout history, more people have died from viral diseases than from wars, and humanity has long lived with the threat of viruses. Since the 20th century alone, viral outbreaks—including COVID-19—have resulted in over 53 million deaths. 

In addition, leading infectious disease experts warn that future pandemics remain highly likely even after COVID-19. This underscores the urgent need for broad-spectrum therapeutics capable of effectively responding to a wide range of viral threats. 

Innovative drug

NEW ANTIVIRAL DRUG XAFTY®

XAFTY® is an innovative antiviral drug developed using Hyundai Bioscience’s advanced technology to address the limitations of conventional antivirals that target only specific viruses. It is a next-generation antiviral therapy with efficacy across a broad range of viral diseases. 

Overcoming Bioavailability Issues

 Niclosamide, the active ingredient in XAFTY®, has demonstrated strong efficacy across a range of viral diseases—including AIDS, hepatitis C, and Ebola—based on international academic research over the past two decades. However, its clinical development has been limited by poor bioavailability, and previous efforts to repurpose it as an antiviral have been unsuccessful.

Hyundai Bioscience has addressed this limitation by applying its advanced drug delivery system (DDS) technology to significantly enhance the bioavailability of niclosamide, resulting in the successful development of XAFTY® as a novel therapeutic solution. 

Published in International Journals

Niclosamide promotes autophagy—the cellular process that removes unnecessary components—helping eliminate viruses such as COVID-19 and MERS. This mechanism has been reported in leading international journals, including Nature journals (2019 and 2021). 

BACKGROUND OF THE BIRTH OF XAFTY®

Affordable Antivirals for Everyone

The Background of XAFTY® 

Hyundai Bioscience began developing XAFTY® after recognizing that, during the COVID-19 pandemic, many patients around the world had no access to effective treatment options. From the outset, we focused on developing a broad-spectrum antiviral that can deliver efficacy regardless of virus type or mutation. As a result, XAFTY® was developed based on niclosamide. 

Even today, many patients worldwide still lack access to treatment—or face prohibitively high costs. Hyundai Bioscience aims to address this unmet need and, in preparation for future pandemics, has developed XAFTY® as a next-generation antiviral designed to provide a more accessible and effective solution.

mobile background

A single drug for multiple 
viral diseases — the promise of 
a broad-spectrum antiviral 
is a goal we all share. 

Hyundai Bioscience

The broad-spectrum antiviral of the Future

In preparation for future pandemics, organizations such as the NIH and the Bill & Melinda Gates Foundation are investing substantial funding to develop response strategies against major viral families that still lack effective treatments. 

Research findings have shown that niclosamide is effective against seven major viral families, with results already published in multiple studies. Just as the advent of penicillin in the 20th century helped humanity overcome the fear of bacterial infections and significantly extended life expectancy, Hyundai Bioscience believes that broad-spectrum antivirals will represent the next major breakthrough. 

A Promise for Humanity

The development of broad-spectrum antivirals represents both a hope for people around the world and a core mission of Hyundai Bioscience. 

To deliver effective treatments for diseases that threaten humanity—such as Mpox, AIDS, and Hepatitis C—we are actively collaborating with leading global institutions and providing research support related to drug development. Through these efforts, we remain committed to advancing broad-spectrum antiviral solutions. 

3 Key Pandemic Challenges

Challenge 01

Difficult
01

Rapid response to mutations is challenging due to the high mutation rate of RNA viruses. 

Challenge 02

Decrease
02

The emergence of resistance reduces the effectiveness of existing antivirals, limiting sustained treatment outcomes. 

Challenge 03

Absence
03

At the onset of a new pandemic, there is often a shortage of effective treatments for early-stage response

Five Major Limitations of Existing Treatments

Existing treatments are often limited in use due to side effects and drug interactions. In addition, early diagnosis remains challenging, making timely treatment difficult. 

01. 

Liver Metabolism Disruption

Some antiviral treatments may interfere with normal liver metabolic processes, potentially affecting drug clearance and safety.

02. 

Risk of Genotoxicity

Certain therapies have been associated with potential genotoxic risks, including mutagenicity concerns.

03. 

Drug Interactions (Multiple Cases)

Some antivirals have extensive drug–drug interaction profiles, limiting co-administration with commonly used medications such as analgesics and antihypertensives.

04. 

Contraindications in Specific Conditions

Use may be restricted in patients with underlying conditions (e.g., liver disease, metabolic disorders, and others), reducing treatment accessibility.

05. 

Limitations in Early Treatment

Because early symptoms can be non-specific and resemble common illnesses, treatment initiation may be delayed until a confirmed diagnosis is made.

XAFTY® Solution

XAFTY® is an antiviral solution with proven safety that enables early treatment. It can be administered at an early stage and delivers superior antiviral efficacy compared to conventional therapies.

FDA Approved

The safety of niclosamide, the active ingredient of XAFTY®, has already been established through FDA approval.

Proven Human Safety

Clinical Phase 1 studies have confirmed its safety in humans.

Enables Early Treatment

With no significant drug interaction concerns, it can be prescribed early, including for influenza.

Superior Antiviral Efficacy

Superior antiviral efficacy demonstrated in preclinical studies by national research institutes.

XAFTY® Difference

The World's First Broad-Spectrum Antiviral

← Scroll left and right →

The Need For XAFTY®

New technologies open new possibilities 

Throughout history, more people have died from viral diseases than from wars, and humanity has long lived with the threat of viruses. Since the 20th century alone, viral outbreaks—including COVID-19—have resulted in over 53 million deaths. 

In addition, leading infectious disease experts warn that future pandemics remain highly likely even after COVID-19. This underscores the urgent need for broad-spectrum therapeutics capable of effectively responding to a wide range of viral threats. 

Innovative drug

NEW ANTIVIRAL DRUG XAFTY®

XAFTY® is an innovative antiviral drug developed using Hyundai Bioscience’s advanced technology to address the limitations of conventional antivirals that target only specific viruses. It is a next-generation antiviral therapy with efficacy across a broad range of viral diseases. 

Overcoming Bioavailability Issues

Niclosamide, the active ingredient in XAFTY®, has demonstrated strong efficacy across a range of viral diseases—including AIDS, hepatitis C, and Ebola—based on international academic research over the past two decades. However, its clinical development has been limited by poor bioavailability, and previous efforts to repurpose it as an antiviral have been unsuccessful.

Hyundai Bioscience has addressed this limitation by applying its advanced drug delivery system (DDS) technology to significantly enhance the bioavailability of niclosamide, resulting in the successful development of XAFTY® as a novel therapeutic solution. 

Published in International Journals

Niclosamide promotes autophagy—the cellular process that removes unnecessary components—helping eliminate viruses such as COVID-19 and MERS. This mechanism has been reported in leading international journals, including Nature journals (2019 and 2021). 

BACKGROUND OF THE
BIRTH OF XAFTY®
Affordable Antivirals for Everyone

The Background of XAFTY® 

Hyundai Bioscience began developing XAFTY® after recognizing that, during the COVID-19 pandemic, many patients around the world had no access to effective treatment options. From the outset, we focused on developing a broad-spectrum antiviral that can deliver efficacy regardless of virus type or mutation. As a result, XAFTY® was developed based on niclosamide. 

Even today, many patients worldwide still lack access to treatment—or face prohibitively high costs. Hyundai Bioscience aims to address this unmet need and, in preparation for future pandemics, has developed XAFTY® as a next-generation antiviral designed to provide a more accessible and effective solution. 

mobile background

A single drug for multiple viral diseases —

the promise of a broad-spectrum antiviral is a goal we all share.

Hyundai Bioscience

The broad-spectrum antiviral of the Future

In preparation for future pandemics, organizations such as the NIH and the Bill & Melinda Gates Foundation are investing substantial funding to develop response strategies against major viral families that still lack effective treatments. 

Research findings have shown that niclosamide is effective against seven major viral families, with results already published in multiple studies. Just as the advent of penicillin in the 20th century helped humanity overcome the fear of bacterial infections and significantly extended life expectancy, Hyundai Bioscience believes that broad-spectrum antivirals will represent the next major breakthrough. 

A Promise for Humanity

The development of broad-spectrum antivirals represents both a hope for people around the world and a core mission of Hyundai Bioscience. 

To deliver effective treatments for diseases that threaten humanity—such as Mpox, AIDS, and Hepatitis C—we are actively collaborating with leading global institutions and providing research support related to drug development. Through these efforts, we remain committed to advancing broad-spectrum antiviral solutions. 

3 Key Pandemic Challenges


Challenge 01

Difficult
01

Rapid response to mutations is challenging due to the high mutation rate of RNA viruses. 


Challenge 02

Decrease
02

The emergence of resistance reduces the effectiveness of existing antivirals, limiting sustained treatment outcomes. 


Challenge 03

Absence
03

At the onset of a new pandemic, there is often a shortage of effective treatments for early-stage response

Five Major Limitations of Existing Treatments

Existing treatments are often limited in use due to side effects and drug interactions. In addition, early diagnosis remains challenging, making timely treatment difficult. 

01.

Liver Metabolism Disruption

Some antiviral treatments may interfere with normal liver metabolic processes, potentially affecting drug clearance and safety.

02.

Risk of Genotoxicity

Certain therapies have been associated with potential genotoxic risks, including mutagenicity concerns.

03.

Drug Interactions (Multiple Cases)

Some antivirals have extensive drug–drug interaction profiles, limiting co-administration with commonly used medications such as analgesics and antihypertensives.

04.

Contraindications in Specific Conditions

Use may be restricted in patients with underlying conditions (e.g., liver disease, metabolic disorders, and others), reducing treatment accessibility.

05.

Limitations in Early Treatment

Because early symptoms can be non-specific and resemble common illnesses, treatment initiation may be delayed until a confirmed diagnosis is made.

XAFTY® Solution

XAFTY® is an antiviral solution with proven safety that enables early treatment.
It can be administered at an early stage and delivers 
superior antiviral efficacy compared to conventional therapies. 

r03-image
FDA Approved
The safety of niclosamide, the active ingredient of XAFTY®, has already been established through FDA approval.
r03-image
Proven Human Safety
Clinical Phase 1 studies have confirmed its safety in humans.
r03-image
Enables Early Treatment
With no significant drug interaction concerns, it can be prescribed early, including for influenza.
r03-image
Superior Antiviral Efficacy
Superior antiviral efficacy demonstrated in preclinical studies by national research institutes.

XAFTY® Difference

Category 
XAFTY®
Conventional COVID-19 Treatments 
Original technology
• Antiviral developed using proprietary DDS technology
• Overcomes low bioavailability with fully domestic technology

• Repurposed drugs not originally developed for COVID-19

• New drug development involves high cost, time, and risk

Innovativeness

• First host cell–targeting oral antiviral

• Effective regardless of viral mutation or resistance

• Vulnerable to viral mutation and resistance

• Suppresses viral activity rather than eliminating the virus

Patient-centered

• Prioritizes patient safety and convenience

• Enables rapid recovery by eliminating the virus

• Limited use due to toxicity concerns

• Requires additional safety validation for new drugs

High accessibility

• Suitable for COVID-19 high-risk groups

• No major drug interaction restrictions

• Many drugs have interaction limitations

• Difficult to prescribe for elderly and high-risk patients

Broad spectrum antiviral

• Capable of responding to 21st-century viral threats

• Effective against epidemic viruses such as Ebola, SARS, and MERS

• Limited scope, making early response difficult

• Restricted in addressing future pandemics

CEO geunwoo jin
Email contact@hyundaibio.com
Tel 1544-3194    |    Fax 053-756-4055

Address  Hyundai Bioscience Co., Ltd., 8th Floor, Botanic Gate, 166, Magokdong-ro, Gangseo-gu, Seoul, 07790, Korea

PR Site

Family Sites

Copyright ⓒ 2026 HYUNDAI BIOSCIENCE All rights reserved.

CEO geunwoo jin    |    Email contact@hyundaibio.com     |    Tel 1544-3194    |    Fax 053-756-4055

Address  Hyundai Bioscience Co., Ltd., 8th Floor, Botanic Gate, 166, Magokdong-ro, Gangseo-gu, Seoul, 07790, Korea

Copyright ⓒ 2026 HYUNDAI BIOSCIENCE All rights reserved.

PR Site

Family Sites